Showing 561 - 580 results of 43,595 for search '(( 50 ((nn decrease) OR (mean decrease)) ) OR ( 5 ((we decrease) OR (teer decrease)) ))', query time: 0.87s Refine Results
  1. 561
  2. 562
  3. 563

    Image 2_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.</p>Methods<p>Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. …”
  4. 564

    Table 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.xlsx by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.</p>Methods<p>Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. …”
  5. 565

    Image 1_Probiotic Limosilactobacillus reuteri KUB-AC5 decreases urothelial cell invasion and enhances macrophage killing of uropathogenic Escherichia coli in vitro study.tiff by Arishabhas Tantibhadrasapa (13929639)

    Published 2024
    “…However, the antibacterial and immune modulatory effects of AC5 on UPEC have never been explored.</p>Methods<p>Here, we investigated both the direct and indirect effects of AC5 against UPEC isolates (UTI89, CFT073, and clinical MDR UPEC AT31) in vitro. …”
  6. 566
  7. 567
  8. 568
  9. 569
  10. 570
  11. 571
  12. 572
  13. 573
  14. 574
  15. 575
  16. 576
  17. 577
  18. 578
  19. 579
  20. 580